VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$1.85 USD
-0.14 (-7.04%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.85 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for VYNE Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -28.45 | -23.21 | -73.33 | -255.57 | -73.70 |
Depreciation/Amortization & Depletion | -0.26 | 0.07 | 0.11 | 54.69 | 0.01 |
Net Change from Assets/Liabilities | 0.06 | 2.28 | 4.78 | -40.33 | 1.89 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.31 | -8.34 | 12.08 | 104.13 | 6.70 |
Net Cash From Operating Activities | -25.34 | -29.20 | -56.37 | -137.08 | -65.10 |
Property & Equipment | 0.00 | 0.00 | 0.00 | -0.11 | -0.01 |
Acquisition/ Disposition of Subsidiaries | 5.00 | 15.67 | 0.00 | 38.64 | 0.00 |
Investments | -62.35 | 0.00 | 1.03 | 50.58 | 41.38 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -57.35 | 15.67 | 1.03 | 89.11 | 41.37 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 82.46 | 1.65 | 76.50 | 61.95 | 4.57 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -36.43 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.07 | 0.00 | -0.29 | -0.14 | 0.43 |
Net Cash from Financing Activities | 82.39 | 1.65 | 39.78 | 61.81 | 4.99 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -0.30 | -11.88 | -15.56 | 13.83 | -18.73 |
Cash at Beginning of Period | 30.98 | 42.86 | 58.42 | 44.58 | 49.51 |
Cash at End of Period | 30.67 | 30.98 | 42.86 | 58.42 | 30.78 |
Diluted Net EPS | -2.78 | -7.28 | -25.54 | -141.73 | -222.30 |
Fiscal Year End for VYNE Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -15.66 | -6.25 | -28.45 | -22.26 | -15.68 |
Depreciation/Amortization & Depletion | -1.39 | -0.78 | -0.26 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | -1.28 | -1.94 | 0.06 | -0.54 | -1.10 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.87 | 0.98 | 3.31 | 2.60 | 1.73 |
Net Cash From Operating Activities | -16.46 | -7.98 | -25.34 | -20.20 | -15.05 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 5.00 | 5.00 | 5.00 |
Investments | 15.45 | -3.57 | -62.35 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 15.45 | -3.57 | -57.35 | 5.00 | 5.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.00 | 82.46 | -0.20 | -0.20 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.01 | 0.00 | -0.07 | -0.07 | -0.02 |
Net Cash from Financing Activities | -0.01 | 0.00 | 82.39 | -0.27 | -0.22 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -1.02 | -11.56 | -0.30 | -15.47 | -10.27 |
Cash at Beginning of Period | 30.67 | 30.67 | 30.98 | 30.98 | 30.98 |
Cash at End of Period | 29.66 | 19.12 | 30.67 | 15.50 | 20.70 |
Diluted Net EPS | -0.22 | -0.15 | 4.06 | -2.01 | -3.09 |